Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer

Lenhard, Miriam; Tsvilina, A.; Schumacher, Lan; Kupka, M.; Ditsch, Nina; Mayr, Doris; Friese, Klaus; Jeschke, Udo

doi:10.1186/1471-2407-12-2

Cited by 49 publications

(50 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GnRs have been implicated in directly regulating EOC survival [11] and proliferation of ovarian cancer cell lines [8], [9]. Further evidence from three former studies suggests that GnRs exert opposing roles in ovarian cancer [7], [11], [37] with LHCGR being linked to favorable prognosis and FSHR being associated to shorter overall survival. Despite the initial enthusiasm driven by projects referring to prostate or breast cancer [38], [39], the response rates to therapies targeting the hypothalamus-pituitary-ovary axis in EOC turned out to be rather low [10].…”

Section: Discussionmentioning

confidence: 99%

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

Follicle stimulating hormone receptor (FSHR) and luteinizing hormone receptor (LHCGR) were demonstrated to impact upon survival of patients suffering from epithelial ovarian cancer (EOC). Though structure wise the G-protein coupled estrogen receptor (GPER/GPR30) is related to FSHR/LHCGR, its prognostic impact in EOC remains controversial. We recently found that FSHR negative patients represent a specific EOC subgroup that may behave differently in respect to both treatment response and prognosis. Hence, the current study aimed to analyze how GPER may interact with the FSHR/LHCGR system in EOC and whether the prognostic significance of GPER in EOC cases (n = 151) may be dependent on the FSHR/LHCGR immunophenotype of the tumor. Ovarian cancer cell lines were used to study how FSH and LH regulate GPER and whether GPER activation differentially affects in vitro cell proliferation in presence/absence of activated FSHR/LHCGR. In EOC tissue, GPER correlated with FSHR/LHCGR and was related to prolonged overall survival only in FSHR/LHCGR negative patients. Although GPER was found to be specifically induced by LH/FSH, GPER agonists (4-Hydroxy-Tamoxifen, G1) reduced EOC cell proliferation only in case of LH/FSH unstimulated pathways. To the same direction, only patients characterized as LHCGR/FSHR negative seem to gain from GPER in terms of survival. Our combined tissue and in vitro results support thus the hypothesis that GPER activation could be of therapeutic benefit in LHCGR/FSHR negative EOC patients. Further studies are needed to evaluate the impact of GPER activation on a clinical scheme.

show abstract

Section: Discussionmentioning

confidence: 99%

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiplication of these values results in the IR-score ranging from 0 (negative) to 12 (strongly positive). Antibody staining used to calculate Spearman’s rho are either published [17,18] (LHCGR, FSHR, hCG) or are in press (PankoMabGEX™).…”

Section: Methodsmentioning

confidence: 99%

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundGlycodelin is a cell surface glycoprotein offering a unique gender specific carbohydrate configuration. Sialylated carbohydrate structures, which are unusual for mammals, characterize Glycodelin isolated from amniotic fluid (Glycodelin A, GdA). Glycodelin in general exerts multiple, partly opposing functions ranging from immunosuppression to cell differentiation. As these markedly influence tumorigenesis, this study aimed to clarify whether expression of different Glycodelin isoforms is related to clinicopathological characteristics and prognosis of ovarian cancer patients. Further the use of Glycodelin as a serum marker in benign and malignant ovarian diseases was evaluated.MethodsOvarian cancer specimens (n = 152) were stained for Glycodelin with carbohydrate and peptide specific antibodies. Associations between Glycodelin expression and histological grading, FIGO stage as well as patient’s prognosis were examined. Glycodelin was correlated to expression of gonadotropin receptors and mucin-1, which are discussed as ovarian cancer tissue markers. In addition, Glycodelin serum concentrations were analyzed in patients suffering from benign (n = 73) or malignant (n = 38) ovarian neoplasias.ResultsGlycodelin A was found to be an independent prognostic marker for poor prognosis in advanced ovarian cancer patients. GdA staining correlated with gonadotropin receptor (FSHR and LHCGR) and with hCG expression. Gd expression showed a positive correlation with a tumour-associated epitope of mucin 1 (TA-MUC1). Further, compared to ovarian cancer, serum Gd was increased in patients with benign ovarian tumors.ConclusionGlycodelin A might be related to tumor aggressiveness and poor clinical outcome in advanced epithelial ovarian cancer. Glycodelin serum levels found in patients suffering from benign ovarian tumors, might contribute to a more global attenuation during progression of these precursor lesions.

show abstract

“…Pre-and post-operative values of β-hCG were measured for prognostic purpose as well as to detect recurrence or metastasis. 7 Pre-operative β-hCG value measured of every patient before surgery or before starting chemo/radiotherapy. Post-operative values of 5 cases (out of 8 cases) of malignant germ cell tumor were measured after one and half month post operatively and after 3 cycles of radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Study of clinical significance and histopathological correlation of serum β- hCG level

Mulla

Inaniya

2017

Int J Res Med Sci

View full text Add to dashboard Cite

Background: β-hCG is a marker useful in diagnosis of gestational trophoblastic disease (GTD), ectopic gestation (EG), spontaneous abortion (SA) and malignant germ cell tumors (MGCT) and it is helpful to clinician as an excellent tumor marker. It is useful to monitor treatment whether tumor is responding to treatment or the disease is progressing.Methods: β-hCG is a marker useful in diagnosis of gestational trophoblastic disease (GTD), ectopic gestation (EG), spontaneous abortion (SA) and malignant germ cell tumors (MGCT) and it is helpful to clinician as an excellent tumor marker. It is useful to monitor treatment whether tumor is responding to treatment or the disease is progressing.Results: p value is highly significant in Gestational Trophoblastic Diseases, EG and SA, as p value is < 0.005 in all these three categories. But in case of MGCT it is 0.452 which is not significant because study group was very small and one case who developed recurrence affected the value significantly. These findings suggest that β-hCG has definitive prognostic role (p value<0.005) in GTD, EG and SA.Conclusions: ELISA is rapid, sensitive, reliable and cost effective test for measurement of β-hCG. Pre-and post-therapeutic β-hCG serum levels seem to be useful in the therapy monitoring of trophoblastic gynaecological conditions i.e. GTD, EG and SA.

show abstract

Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer

Cited by 49 publications

References 45 publications

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients

The G-Protein Coupled Estrogen Receptor (GPER/GPR30) is a Gonadotropin Receptor Dependent Positive Prognosticator in Ovarian Carcinoma Patients

Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients

Study of clinical significance and histopathological correlation of serum β- hCG level

Contact Info

Product

Resources

About